China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase II clinical study for its Category 1 biologic product GZR18, a novel glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-weekly administration.
Study Details
The Phase Ib/IIb study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of GZR18 in Chinese adult patients with type 2 diabetes and those who are obese or overweight.
Competitive Landscape
Similar products already available in China include Eli Lilly’s Trulicity (dulaglutide), Novo Nordisk’s Ozempic (semaglutide), and Hansoh Pharma’s polyethylene glycol loxenatide.-Fineline Info & Tech
